ABBV-969 dual-targeting ADC #ESMO26
MOA = PSMA/STEAP1— TOPO1
Deep responses in metastatic castration-resistant prostate cancer
Surely this one can beat Docetaxel?
2331 浏览 · 46 赞 · 18 转发 · 1 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org- Raffaele Colombo@raffcolo
@tompowles1 @OncoAlert But how many patients dosed at above potential RP2D? Most likely those at 10 and 12.5 mg/kg. 8 mg/kg TBD…
来源：Tom Powles · x.com